Is Greenwich LifeSciences, Inc. (GLSI) a Buy, Sell, or Hold?
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$19.54 USD
$0.53 (2.79%)
- Volume
- 46.62K
- Average Volume
- 144.58K
- Market Capitalization
- $286.81M
- P/E Ratio
- -12.45
- Dividend Yield
- 0.00%
- Price Target
- $50.00
- Year High
- $34.10
- Year Low
- $7.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.01
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Snehal S. Patel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GLSI |
| CUSIP | 396879108 |
| CIK | 0001799788 |
| Web | https://greenwichlifesciences.com |
| Phone | 832 819 3232 |
| Currency | USD |
| Employees | 13 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.01 |
| Quick Ratio | 2.01 |
| Cash Ratio | 2.01 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.88 |
| Price / Cash Flow | -22.44 |
| Price / Book | 54.00 |
Price Target and Rating
| Average Stock Price Forecast | $50.00 |
| High Stock Price Forecast | $50.00 |
| Low Stock Price Forecast | $50.00 |
| Forecast Upside/Downside | -60.92% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.43 |
| Trailing P/E Ratio | -12.45 |
| PEG Ratio | 0.58 |
| P/E Growth | 0.58 |
| Net Income | $-19.36M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -941.06% |
| Return on Assets | -207.10% |
Financials Score
| AltmanZ Score | 12.76 |
| Piotroski Score | 2.00 |
| Working Capital | 5.27M |
| Total Assets | 10.51M |
| Ebit | -21.76M |
| Market Cap | 273.6M |
| Total Liabilities | 5.24M |
Poll Results
About Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018. ...
2026-07-09 06:00:00
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.
2026-06-01 08:15:00
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026.
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
2026-06-01 06:00:00
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
2026-06-01 06:00:00
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
2026-05-22 16:30:00
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission.
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
2026-05-22 16:30:00
STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The notice has no immediate effect on the listing or trading of the Company's common stock, which continues to trade on the Nasdaq Capital Market under the symbol "GLSI."
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
2026-04-30 06:00:00
STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
2026-04-30 06:00:00
STAFFORD, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.
Frequently Asked Questions
-
What is the current Greenwich LifeSciences, Inc. (GLSI) stock price?
-
Greenwich LifeSciences, Inc.(NASDAQ:GLSI) stock price is $19.54 in the last trading session. During the trading session, GLSI stock reached the peak price of $34.1 while $7.78 was the lowest point it dropped to. The percentage change in GLSI stock occurred in the recent session was 2.79% while the dollar amount for the price change in GLSI stock was $0.53.
-
GLSI's industry and sector of operation?
-
The NASDAQ listed GLSI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GLSI?
-
Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director
Christine T. Fischette | Vice President of Business Development
Frank Joseph Daugherty | Chief Medical Officer & Director
Jaye L. Thompson | Vice President Clinical & Regulatory Affairs
Eric Rothe | Founder & Independent Director -
How many employees does GLSI have?
-
Number of GLSI employees currently stands at 13. GLSI operates from Building 14, Stafford, TX 77477, US.
-
Link for GLSI official website?
-
Official Website of GLSI is: https://greenwichlifesciences.com
-
How do I contact GLSI?
-
GLSI could be contacted at phone #832 819 3232 and can also be accessed through its website. GLSI operates from Building 14, Stafford, TX 77477, US.
-
How many shares of GLSI are traded daily?
-
The average number of GLSI shares traded daily for last 3 months was 144.58K.
-
What is the market cap of GLSI currently?
-
The market value of GLSI currently stands at $286.81M with its latest stock price at $19.54